

Datasheet for 100-401-266

NFkB p65 (RelA) Phospho S529 Antibody

Overview

Description:	Anti-NFkB p65 (Rel A) pS529 (RABBIT) Antibody - 100-401-266
Item No.:	100-401-266
Size:	100 µL
Applications:	ELISA, WB, IF
Reactivity:	Human
Host Species:	Rabbit

Product Details

Background: NFkB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkB bound to IκB. NFkB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFkB1) subunits. Other identified subunits include p52 (NFkB2), cRel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkB subunit p65, similar to p50/p65 heterodimers. Low levels of p52 and p50 homodimers can also exist in cells. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IκB-alpha. IκB-alpha binds to the p65 subunit preventing nuclear localization and DNA binding. Activators mediate a rapid phosphorylation of IκB by IκB kinase (IKK) which results in subsequent ubiquitination and proteolytic degradation. NFkB is then transported to the nucleus, where it activates transcription of target genes through binding to NFkB target sequences within the promoter. The HTLV-I protein Tax can induce constitutive NFkB activation through phosphorylation of both IκB-alpha and IκB-beta. The transforming protein Tax inhibits p53 transcriptional activity through the NFkB signaling pathway, specifically via the p65 (RelA) subunit. Anti-NFkB antibody is ideal for Cell Biology, Nuclear Signaling, Neuroscience and Signal Transduction Research.

Synonyms:	rabbit anti-NFkB p65 pS529 Antibody, rabbit anti-RelA pS529 Antibody, NFkB, nfkb, NF-kB, NF-kappaB, NFkappaB
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	Antiserum

Target Details

Gene Name:	RELA
Reactivity:	Human
PTM Specificity:	Phosphorylation
Immunogen Type:	Conjugated Peptide
Immunogen:	NFkB p65 (Rel A) peptide corresponding to a region near phospho Serine 529 of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).
Purity/Specificity:	Anti-NFkB p65 (RelA) Phospho S529 Antibody was prepared from monospecific antiserum by delipidation and defibrination. This phospho specific polyclonal antibody is specific for phosphorylated pS529 human p65. Reactivity with non-phosphorylated p65 is minimal. Cross reactivity with pS529 phosphorylated p65 from mouse, rat or other species has not been determined.
Relevant Links:	<ul style="list-style-type: none">• UniProtKB - Q04206• NCBI - 223468676• GenelD - 5970

Application Details

Tested Applications:	ELISA, WB
Suggested Applications:	IF (Based on references)
Application Note:	Anti-phospho NFkB antibody reacts human pS529 p65 and shows minimal reactivity by western blot with non-phosphorylated p65 and minimal reactivity by ELISA against the non-phosphorylated form of the immunizing peptide. Although not tested, this antibody is likely functional in immunohistochemistry and immunoprecipitation.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	1:5,000 - 1:25,000
IHC:	1:200 - 1:1,000
WB:	1:500 - 1:3,000

Formulation


Physical State:	Liquid (sterile filtered)
------------------------	---------------------------

Concentration:	75 mg/mL by Refractometry
Buffer:	None
Preservative:	0.1% (w/v) Sodium Azide
Stabilizer:	None

Shipping & Handling


Shipping Condition:	Dry Ice
Storage Condition:	Store NFkB p65 (RelA) Phospho S529 Antibody at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration:	Expiration date is one (1) year from date of receipt.

Images



Western Blot

Botanical extracts block the IL-1 β -induced phosphorylation and nuclear translocation of p65 in chondrocytes. Western blot analysis of IL-1 β -treated nuclear extracts. Serum-starved chondrocytes (0.1 \times 10⁶ cells/mL) were pretreated with botanical extracts (10 μ g/mL each) for 4 hours followed by cotreatment with 10 μ g/mL IL-1 β and botanical extracts for 1 h. Some chondrocyte cultures remained either untreated or were treated with 10 μ g/mL botanical extracts (each alone) or with 10 μ g/mL IL-1 β alone for 1 h. Nuclear extracts were probed for phospho p65, (I) by western blot analysis using antibodies to p65, phospho-specific p65, and PARP (II, control). Treatment of chondrocytes with IL-1 β (10 μ g/mL) revealed a clear increase in expression of phospho-p65 in the nuclear extracts (I). Co-treatment of chondrocytes with botanical extracts (all three) completely abolished the IL-1 β -dependent activation of phospho p65 in the nucleus (I). Synthesis of PARP remained unaffected in nuclear extracts (II). Data shown are representative of three independent experiments. Treatments: C (untreated control); IL-1 β ; RC (Rosa canina); SA (Salix alba); UD (Urtica dioica). Figure provided by CiteAb. Source: Evid Based Complement Alternat Med, PMID: 22474508.





Immunofluorescence Microscopy

Tendoactive® inhibited IL-1 β -induced nuclear translocation of phospho p65 revealed by immunofluorescence microscopy. Tenocytes cultures either served as controls (I, not treated) or were treated with 10 ng/ml IL-1 β alone for 10 min or pre-treated first with Tendoactive® (250 μ g/ml) for 1h alone and then were co-treated with 10 ng/ml IL-1 β for 10 min before indirect immunolabeling with anti-phospho p65 antibody and FITC-coupled secondary antibodies. In control cells anti-phospho p65 labelling was restricted to the cytoplasm (I). Cells treated with IL-1 β alone revealed nuclear translocation of phospho p65 (II) that was partly inhibited by co-treatment with Tendoactive® (III). Data shown are representative of three independent experiments. X160. Fig 5. PMID: 21751149.

Western Blot

TNF Induces phosphorylation of p65 in KBM-5 cells. Nuclear protein lysates prepared after 0, 5, 10, 15, 30 and 60 minutes of 0.1 nM TNF treatment of KBM-5 cells shows inducible phosphorylation using phospho specific polyclonal anti-human pS529 p65. Anti-beta-actin staining confirms loading of equivalent amounts of protein. HRP conjugated Gt-anti-Rabbit IgG was used to develop the blot using a chemiluminescent detection method. Other detection methods will yield similar results. Data contributed by Aggarwal BB, personal communication.





Western Blot

Anti-pS529 shows phospho p65 staining in carcinoma cells. western blot of total protein lysates from various human head and neck tumors shows phospho p65 staining in tumor cell lines using phospho specific polyclonal anti-human pS529 p65. Lanes 1-6 contain protein lysates from human squamal carcinoma cell lines. Lane 7 is a protein lysate from a primary culture of human keratinocytes. Lane 8 contains protein lysate from ATCC SCC9 cells (also a head and neck squamal carcinoma). Lane 9 contains lysate from EGF-induced human derived A431 cells. Lane 10 (not shown) contains a molecular weight standard. Concurrent staining with anti-beta microtubulin (not shown) was used to confirm equal protein loading in all lanes. HRP conjugated Gt-anti-Rabbit IgG was used to develop the blot using a chemiluminescent detection method. Other detection methods will yield similar results. Data contributed by Yu, M., NIH, personal communication.

References

- Liu X. et al. Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas. *Blood Adv* (2020)
- Ryu, S et al. Suppression of Propionibacterium acnes Infection and the Associated Inflammatory Response by the Antimicrobial Peptide P5 in Mice. *PLoS One* (2015)
- Shakibaei et al. Botanical Extracts from Rosehip (*Rosa canina*), Willow Bark (*Salix alba*), and Nettle Leaf (*Urtica dioica*) Suppress IL-1 β -Induced NF- κ B Activation in Canine Articular Chondrocytes. *Evid Based Complement Alternat Med.* (2012)
- Shakibaei et al. Anti-inflammatory and anti-catabolic effects of TENDOACTIVE[®] on human tenocytes in vitro. *Histol. Histopathol.* (2011)
- Castier et al. Role of NF-kappaB in flow-induced vascular remodeling. *Antioxid. Redox Signal.* (2009)
- Zhao et al. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. *Biochem. Pharmacol.* (2008)
- Shakibaei et al. Suppression of NF-kappaB activation by curcumin leads to inhibition of expression of cyclo-oxygenase-2 and matrix metalloproteinase-9 in human articular chondrocytes: Implications for the treatment of osteoarthritis. *Biochem. Pharmacol.* (2007)
- Schulze-Tanzil G et al. Effects of curcumin (diferuloylmethane) on nuclear factor-kB signaling in interleukin-1b-stimulated chondrocytes. *Ann NY Acad Sci.* (2004)
- Ashikawa et al. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. *J Immunol* (2002)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.